BioMedical Materials (BMM) Consortium

At a Glance
  • Status: Completed Consortium
  • Year Launched: 2007
  • Initiating Organization: Government of the Netherlands
  • Initiator Type: Government
  • No disease focus
  • Location: Europe
BMMC

Abstract

The BioMedical Materials (BMM) consortium focuses on advancing the use of new materials to biomedical research. As a public-private partnership, the consortium includes the participation of over 50 leading institutions, corporations, and health foundations, with support from the government of the Netherlands.

Mission

The BioMedical Materials (BMM) consortium aims to develop new materials for biomedical applications. Established in 2007 as a pre-competitive partnership, BMM has brought together over 50 partners from the private and public sectors to develop new therapies and products to combat organ and tissue failure. The current portfolio includes 18 pre-clinical projects in research domains at the interface of a variety of prevalent diseases and technologies, to advance the creation of therapies and other medical products.

Structure & Governance

The BMM Executive Board is responsible for the day-to-day management of BMM, for its financials, for building and expanding the BMM partnership, for the monitoring of the progress of the various BMM projects, and for the support by the BMM office in Geleen.
 
The BMM Supervisory Board provides oversight to the consortium’s project portfolio, following the advice of the BMM International Scientific Advisory Board, and the approval of the Annual Financial Accounts of BMM. The BMM Supervisory Board also appoints the members of the BMM Executive Board. The members of the BMM Supervisory Board are selected form the group of BMM partners.
 
Representatives of all BMM partners meet annually in the General Assembly of BMM partners. In this meeting the partners are informed about the progress of the BMM projects and activities and jointly they discuss the options for the future of the BMM partnership. The meeting is usually organized co-incidentally with the scientific BMM Annual Meeting.
 
The International Scientific Advisory Board (ISAB) ensures the scientific integrity and provides oversight to the BMM projects. The ISAB reports to the Supervisory Board for the approval of project proposals and annually on the progress and continuation of the projects. The ISAB comprises of 7 international specialists in the technological and disease areas of BMM.

Financing

The consortium operates with a € 90 M budget, provided by the government of the Netherlands

Impact / Accomplishment

The BMM Valorization Grant has led to the start of the first spin-off company based on the outcome of a BMM project. Additional accomplishments are provided in the consortium’s annual report.

Homepage

http://www.bmm-program.nl/SITE/PUBLIC/GO/?rid=1

Points of Contact

BioMedical Materials
Urmonderbaan 20/A
NL-6167 RD GELEEN
NETHERLANDS
T +31 (46) 702 2280
E info@bmm-program.nl

Sponsors & Partners

Academic Medical Center

Erasmus MC                       

Leiden University Medical Center

Maastricht UMC+

University of Groningen

TUDelft              

Technische Universiteit Eindhoven

UMCG

University Medical Center Utrecht

Radboud University Medical Center

Universiteit Leiden The Netherlands

Universiteit Utrecht

Penn Medicine

University of Twente

Universitat Zurich

VUmc

AXLE International

BAAT Medical Engineering

Bio Comp

Biocompatibles

Biomet

Cam Bioceramics

CellCoTec

Dolphys             

DSM                

European Medical Contract Manufacturing

FeyeCon

Fortimedix

Ft. Innovations B.V.

Fujifilm

Genus Biotech

Hartstichting

InGell

Innocore Pharmaceuticals

MagnaMedics

Nanomi Monosphere Technology

Nierstichting

NT-MDT

PCI Biotech

Percuros

PharmaCell

Philips

Reumafonds Dutch Arthritis Foundation

SolMates

SupraPolix

SyMO-Chem

TNO Innovation for Life

Xeltis

Xpand Biotechnology

ZF Screens.


Last Updated: 04/22/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.